Hope for Families Affected by Sickle Cell Disease
Sickle cell disease (SCD) is a common inherited blood disorder, affecting 70,000 to 80,000 Americans, with approximately 300,000 babies born each year worldwide with the disease.
Aldevron Releases GMP-Grade SpyFi™ Cas9 Nuclease
Product is the result of a partnership with Integrated DNA Technologies, Inc., and provides clinical stage clients with a critical raw material
Aldevron is announcing the release of GMP SpyFi Cas9 Nuclease for clinical and commercial applications. SpyFi Cas9 Nuclease, the trade name for Aldevron’s research grade and GMP products, is the direct result of a partnership with Integrated DNA Technologies, Inc. (IDT). The advantages of SpyFi Cas9 Nuclease include reduced off-target effects combined with clinically relevant on-target activity.
Aldevron to provide new GMP Cas9 nuclease through agreement with Integrated DNA Technologies
Aldevron and Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFiTM Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.
Aldevron Announces Availability of GMP SpCas9
Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services, announces the availability of GMP-grade SpCas9 nuclease for use in clinical development programs. Aldevron’s GMP SpCas9 is designed to accelerate gene editing clinical trials and commercial applications by providing an immediate enzyme supply; thereby eliminating months typically associated with contract GMP production and testing.